The stock has a 36-month beta value of 1.63.
The public float for BGLC is 11.03M, and at present, short sellers hold a 2.12% of that float. On April 07, 2025, the average trading volume of BGLC was 728.05K shares.
BGLC) stock’s latest price update
BioNexus Gene Lab Corp (NASDAQ: BGLC)’s stock price has gone decline by -18.40 in comparison to its previous close of 0.29, however, the company has experienced a -6.20% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-07 that KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation.
BGLC’s Market Performance
BioNexus Gene Lab Corp (BGLC) has seen a -6.20% fall in stock performance for the week, with a -32.00% decline in the past month and a -41.20% plunge in the past quarter. The volatility ratio for the week is 19.89%, and the volatility levels for the past 30 days are at 10.66% for BGLC. The simple moving average for the past 20 days is -21.98% for BGLC’s stock, with a -38.10% simple moving average for the past 200 days.
BGLC Trading at -31.31% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.54% of loss for the given period.
Volatility was left at 10.66%, however, over the last 30 days, the volatility rate increased by 19.89%, as shares sank -36.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.86% lower at present.
During the last 5 trading sessions, BGLC fell by -6.20%, which changed the moving average for the period of 200-days by -47.87% in comparison to the 20-day moving average, which settled at $0.3007. In addition, BioNexus Gene Lab Corp saw -16.12% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.13 for the gross margin
The net margin for BioNexus Gene Lab Corp stands at -0.1. The total capital return value is set at -0.12. Equity return is now at value -9.87, with -8.38 for asset returns.
Based on BioNexus Gene Lab Corp (BGLC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.68. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -56.5.
Currently, EBITDA for the company is -2.49 million with net debt to EBITDA at 5.14. When we switch over and look at the enterprise to sales, we see a ratio of 0.03. The receivables turnover for the company is 6.5for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To sum up, BioNexus Gene Lab Corp (BGLC) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
